Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists (Q42755574)

6 November 2017

Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists (English)

1 reference

6 November 2017

1 reference

Howard Huaihan Pai

1

1 reference

6 November 2017

Tom Pickles

2

1 reference

6 November 2017

Mira Keyes

3

1 reference

6 November 2017

Stuart Jones

4

1 reference

6 November 2017

Rachel E McDonald

5

1 reference

6 November 2017

Mary Lesperance

6

1 reference

6 November 2017

Eric Berthelet

7

1 reference

6 November 2017

1 June 2011

1 reference

Canadian Urological Association journal

6 November 2017

1 reference

6 November 2017

5

1 reference

6 November 2017

3

1 reference

6 November 2017

173-179

1 reference

Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer

6 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

The International Index of Erectile Function (IIEF): a state-of-the-science review

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

What happens to testosterone after prostate radiation monotherapy and does it matter?

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114026

A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy

16 August 2018

1 reference

12 December 2020

Testicular doses in definitive radiation therapy for localized prostate cancer

1 reference

12 December 2020

Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration

1 reference

12 December 2020

Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive

1 reference

12 December 2020

Serum testosterone levels after external beam radiation for clinically localized prostate cancer

1 reference

12 December 2020

Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin

1 reference

12 December 2020

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.5489/CUAJ.10102

1 reference

6 November 2017

1 reference

6 November 2017

1 reference